- STRENGTHENS CELL-BASED SCREENING AND REAGENT PLATFORM AT EVOTEC'S HAMBURG SITE
- ADDS HIGH-MARGIN BUSINESS WITH AN EXPECTED REVENUE OF MORE THAN €1.0 M IN 2013
- INITIAL PURCHASE PRICE OF APPROX €1.2 M IN CASH PLUS AN EARN-OUT PAYMENT DEPENDENT ON BUSINESS PERFORMANCE
Despite cash requirements for the transaction and integration of approximately €1.2 m in 2012, Evotec confirms its cash guidance for the full year of more than €60 m.ABOUT CELL CULTURE SERVICE GMBH (CCS) CCS is a supplier of custom cells and cell based reagents for the drug discovery process. The service provider generates tailor-made recombinant cell lines and develops cell based assays for various applications in pharmaceutical and biotechnology R&D. For HTS campaigns CCS produces bulk amounts of assay-ready recombinant, non-recombinant or transiently transfected mammalian cells and preparations derived thereof. Due to its semi-automated and scalable but flexible processes and its integrated quality management system, CCS provides cells of high value which meet individual customer needs. Working from its headquarter in Hamburg, Germany or its subsidiary in Monmouth Junction, New Jersey, CCS supports most of the big pharmaceutical and major biotechnology companies in Europe and the USA in their effort to discover new therapeutics. www.cellcultureservice.com ABOUT EVOTEC AG Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, MedImmune/Astra Zeneca, Novartis, Ono Pharmaceutical and Roche. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include a strategic alliance with Roche for the development of subtype-selective NMDA receptor antagonists for use in treatment-resistant depression as well as other partnerships with Boehringer Ingelheim, MedImmune and with Andromeda (Teva) in the field of diabetes. For additional information please go to www.evotec.com. FORWARD-LOOKING STATEMENTS: Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
CONTACT: Dr Mario Polywka Chief Operating Officer +44.(0)1235.44 16 76 +44.(0)1235.86 31 39 Fax firstname.lastname@example.org Evotec AG Manfred Eigen Campus Essener Bogen 7 22419 Hamburg (Germany)